TrialBMC cancer2013

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.

Masanori Noguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.